Completed PHASE3 INTERVENTIONAL 2-arm NCT02872103

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Sponsor: EVIVE Biotechnology

Conditions Breast Cancer Neutropenia

Interventions F-627 Placebo

Updated 12 times since 2017 Last updated: Apr 9, 2021 Started: Aug 31, 2016 Primary completion: Dec 20, 2017 Completion: Dec 20, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02872103, this PHASE3 trial focuses on Breast Cancer and Neutropenia and remains completed. Sponsored by EVIVE Biotechnology, it has been updated 12 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Mar 2022 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jun 2021 — Mar 2022 [monthly]

Completed PHASE3
Jan 2021 — Jun 2021 [monthly]

Completed PHASE3
Apr 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Apr 2019 [monthly]

Completed PHASE3
Feb 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Feb 2017 — Feb 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EVIVE Biotechnology

Data source: EVIVE Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Princeton, United States